| # | Title | Journal | Year | Citations |
|---|
| 1 | Nanoparticles for drug delivery in cancer treatment | Urologic Oncology: Seminars and Original Investigations | 2008 | 619 |
| 2 | A robust methodology to study urine microRNA as tumor marker: microRNA-126 and microRNA-182 are related to urinary bladder cancer | Urologic Oncology: Seminars and Original Investigations | 2010 | 572 |
| 3 | Micro-RNA profiling in kidney and bladder cancers | Urologic Oncology: Seminars and Original Investigations | 2007 | 566 |
| 4 | Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues | Urologic Oncology: Seminars and Original Investigations | 1995 | 465 |
| 5 | Commentary on “Integrative clinical genomics of advanced prostate cancer” . Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM, Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W, Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY, Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R, Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE, Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G, Sougnez C, Gupta M, Yu EY, Mostaghel | Urologic Oncology: Seminars and Original Investigations | 2017 | 307 |
| 6 | New frontiers in nanotechnology for cancer treatment | Urologic Oncology: Seminars and Original Investigations | 2008 | 274 |
| 7 | Incidence trends in primary malignant penile cancer | Urologic Oncology: Seminars and Original Investigations | 2007 | 256 |
| 8 | Naturally-occurring canine transitional cell carcinoma of the urinary bladder A relevant model of human invasive bladder cancer | Urologic Oncology: Seminars and Original Investigations | 2000 | 240 |
| 9 | Molecular pathways of urothelial development and bladder tumorigenesis | Urologic Oncology: Seminars and Original Investigations | 2010 | 228 |
| 10 | Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon α-2B for reducing recurrence of superficial bladder cancer☆ | Urologic Oncology: Seminars and Original Investigations | 2006 | 217 |
| 11 | UroVysion FISH test for detecting urothelial cancers: Meta-analysis of diagnostic accuracy and comparison with urinary cytology testing | Urologic Oncology: Seminars and Original Investigations | 2008 | 214 |
| 12 | Prospective analysis of sensitivity and specificity of urinary cytology and other urinary biomarkers for bladder cancer | Urologic Oncology: Seminars and Original Investigations | 2015 | 212 |
| 13 | The impact of variant histology on the outcome of bladder cancer treated with curative intent | Urologic Oncology: Seminars and Original Investigations | 2009 | 211 |
| 14 | Clinical application of a 3D ultrasound-guided prostate biopsy system | Urologic Oncology: Seminars and Original Investigations | 2011 | 205 |
| 15 | Multiparametric magnetic resonance imaging vs. standard care in men being evaluated for prostate cancer: A randomized study | Urologic Oncology: Seminars and Original Investigations | 2015 | 197 |
| 16 | Molecular genetics of bladder cancer: Emerging mechanisms of tumor initiation and progression | Urologic Oncology: Seminars and Original Investigations | 2010 | 188 |
| 17 | Mechanisms mediating androgen receptor reactivation after castration | Urologic Oncology: Seminars and Original Investigations | 2009 | 181 |
| 18 | Combining urinary detection of TMPRSS2:ERG and PCA3 with serum PSA to predict diagnosis of prostate cancer | Urologic Oncology: Seminars and Original Investigations | 2013 | 181 |
| 19 | Bladder cancer in the elderly | Urologic Oncology: Seminars and Original Investigations | 2009 | 174 |
| 20 | The prostate cancer-up-regulated long noncoding RNA PlncRNA-1 modulates apoptosis and proliferation through reciprocal regulation of androgen receptor | Urologic Oncology: Seminars and Original Investigations | 2013 | 174 |
| 21 | The “male lumpectomy”: Focal therapy for prostate cancer using cryoablation results in 48 patients with at least 2-year follow-up | Urologic Oncology: Seminars and Original Investigations | 2008 | 170 |
| 22 | Chronic inflammation and bladder cancer | Urologic Oncology: Seminars and Original Investigations | 2007 | 164 |
| 23 | Bladder cancer or bladder cancers? Genetically distinct malignant conditions of the urothelium | Urologic Oncology: Seminars and Original Investigations | 2010 | 156 |
| 24 | Mode of presentation of renal cell carcinoma provides prognostic information | Urologic Oncology: Seminars and Original Investigations | 2002 | 153 |
| 25 | Transperineal 3D mapping biopsy of the prostate: An essential tool in selecting patients for focal prostate cancer therapy | Urologic Oncology: Seminars and Original Investigations | 2008 | 152 |
| 26 | Gender, racial and age differences in bladder cancer incidence and mortality | Urologic Oncology: Seminars and Original Investigations | 2004 | 147 |
| 27 | Commentary on “AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.” Antonarakis ES, Lu C, Wang H, Luber B, Nakazawa M, Roeser JC, Chen Y, Mohammad TA, Chen Y, Fedor HL, Lotan TL, Zheng Q, De Marzo AM, Isaacs JT, Isaacs WB, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J, Division of Urologic Oncology, Department of Urology, University of Michigan, MI. N Engl J Med 2014; 371(11):1028-38. | Urologic Oncology: Seminars and Original Investigations | 2016 | 145 |
| 28 | The prostate-specific membrane antigen: Lessons and current clinical implications from 20 years of research | Urologic Oncology: Seminars and Original Investigations | 2014 | 142 |
| 29 | Phase II trial of oral 1,25-dihydroxyvitamin D (calcitriol) in hormone refractory prostate cancer | Urologic Oncology: Seminars and Original Investigations | 1995 | 141 |
| 30 | Granulocyte-macrophage colony-stimulating factor−transduced allogeneic cancer cellular immunotherapy: The GVAX® vaccine for prostate cancer | Urologic Oncology: Seminars and Original Investigations | 2006 | 141 |
| 31 | An open label, single-arm, phase II multicenter study of the safety and efficacy of CG0070 oncolytic vector regimen in patients with BCG-unresponsive non–muscle-invasive bladder cancer: Interim results | Urologic Oncology: Seminars and Original Investigations | 2018 | 140 |
| 32 | SELECT: the selenium and vitamin E cancer prevention trial | Urologic Oncology: Seminars and Original Investigations | 2003 | 138 |
| 33 | Variant (divergent) histologic differentiation in urothelial carcinoma is under-recognized in community practice: Impact of mandatory central pathology review at a large referral hospital | Urologic Oncology: Seminars and Original Investigations | 2013 | 136 |
| 34 | Bladder recurrence after surgery for upper urinary tract urothelial cell carcinoma: Frequency, risk factors, and surveillance | Urologic Oncology: Seminars and Original Investigations | 2011 | 135 |
| 35 | Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer | Urologic Oncology: Seminars and Original Investigations | 2011 | 134 |
| 36 | Use of serial multiparametric magnetic resonance imaging in the management of patients with prostate cancer on active surveillance | Urologic Oncology: Seminars and Original Investigations | 2015 | 133 |
| 37 | A prospective clinical trial of green tea for hormone refractory prostate cancer: An evaluation of the complementary/alternative therapy approach | Urologic Oncology: Seminars and Original Investigations | 2005 | 132 |
| 38 | Natural history of untreated renal cell carcinoma with venous tumor thrombus | Urologic Oncology: Seminars and Original Investigations | 2013 | 125 |
| 39 | Randomized intergroup comparison of bacillus calmette-guerin immunotherapy and mitomycin C chemotherapy prophylaxis in superficial transitional cell carcinoma of the bladder a southwest oncology group study | Urologic Oncology: Seminars and Original Investigations | 1995 | 124 |
| 40 | Permanent flank bulge is a consequence of flank incision for radical nephrectomy in one half of patients | Urologic Oncology: Seminars and Original Investigations | 2004 | 124 |
| 41 | ERK(MAPK) activity as a determinant of tumor growth and dormancy; regulation by p38(SAPK) | Urologic Oncology: Seminars and Original Investigations | 2004 | 123 |
| 42 | Sex-specific hormone receptors in urothelial carcinomas of the human urinary bladder: A comparative analysis of clinicopathological features and survival outcomes according to receptor expression | Urologic Oncology: Seminars and Original Investigations | 2011 | 120 |
| 43 | Statistical consideration for clinical biomarker research in bladder cancer | Urologic Oncology: Seminars and Original Investigations | 2010 | 119 |
| 44 | Clinical, prognostic, and therapeutic aspects of urachal carcinoma—A comprehensive review with meta-analysis of 1,010 cases | Urologic Oncology: Seminars and Original Investigations | 2016 | 119 |
| 45 | Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Guérin | Urologic Oncology: Seminars and Original Investigations | 2013 | 116 |
| 46 | KRN951, a highly potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, has antitumor activities and affects functional vascular properties | Urologic Oncology: Seminars and Original Investigations | 2007 | 114 |
| 47 | A systematic review and meta-analysis on the oncological long-term outcomes after trimodality therapy and radical cystectomy with or without neoadjuvant chemotherapy for muscle-invasive bladder cancer | Urologic Oncology: Seminars and Original Investigations | 2018 | 113 |
| 48 | Commentary on “Abiraterone in metastatic prostate cancer without previous chemotherapy.” Ryan CJ, Smith MR, de Bono JS, Molina A, Logothetis CJ, de Souza P, Fizazi K, Mainwaring P, Piulats JM, Ng S, Carles J, Mulders PF, Basch E, Small EJ, Saad F, Schrijvers D, Van Poppel H, Mukherjee SD, Suttmann H, Gerritsen WR, Flaig TW, George DJ, Yu EY, Efstathiou E, Pantuck A, Winquist E, Higano CS, Taplin ME, Park Y, Kheoh T, Griffin T, Scher HI, Rathkopf DE; COU-AA-302 Investigators, Genitourinary Medical Oncology P | Urologic Oncology: Seminars and Original Investigations | 2013 | 112 |
| 49 | The accuracy of multiparametric MRI in men with negative biopsy and elevated PSA level—Can it rule out clinically significant prostate cancer? | Urologic Oncology: Seminars and Original Investigations | 2014 | 110 |
| 50 | Change in expression of miR-let7c, miR-100, and miR-218 from high grade localized prostate cancer to metastasis | Urologic Oncology: Seminars and Original Investigations | 2011 | 109 |
